139 related articles for article (PubMed ID: 21852387)
21. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
23. Avastin: more questions than answers. .
Desjardins A; Sampson JH
J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
[No Abstract] [Full Text] [Related]
24. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.
Johnson DR; Leeper HE; Uhm JH
Cancer; 2013 Oct; 119(19):3489-95. PubMed ID: 23868553
[TBL] [Abstract][Full Text] [Related]
25. Rare serious complications of erlotinib therapy.
Kapoor S
Acta Neurochir (Wien); 2013 Apr; 155(4):743. PubMed ID: 23361636
[No Abstract] [Full Text] [Related]
26. Response to: "rare serious complications of erlotinib therapy".
D'Alessandris QG; Pallini R
Acta Neurochir (Wien); 2013 Apr; 155(4):745. PubMed ID: 23275073
[No Abstract] [Full Text] [Related]
27. Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
Malkki H
Nat Rev Neurol; 2014 Apr; 10(4):179. PubMed ID: 24638136
[No Abstract] [Full Text] [Related]
28. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
29. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu YH; Ferl GZ; Ng CM
Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Castro BA; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
[TBL] [Abstract][Full Text] [Related]
31. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
32. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
[TBL] [Abstract][Full Text] [Related]
33. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
34. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
[TBL] [Abstract][Full Text] [Related]
35. The future of antiangiogenic treatment in glioblastoma.
Chinot OL; Reardon DA
Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab in glioblastoma--still much to learn.
Fine HA
N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
[No Abstract] [Full Text] [Related]
37. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for acute neurologic deterioration in patients with glioblastoma.
Kaley T; Nolan C; Carver A; Omuro A
CNS Oncol; 2013 Sep; 2(5):413-8. PubMed ID: 25054664
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis inhibitors in tackling recurrent glioblastoma.
Hundsberger T; Reardon DA; Wen PY
Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
